These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
548 related articles for article (PubMed ID: 31196931)
1. Detection of Solomon JP; Hechtman JF Cancer Res; 2019 Jul; 79(13):3163-3168. PubMed ID: 31196931 [TBL] [Abstract][Full Text] [Related]
2. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467 [TBL] [Abstract][Full Text] [Related]
3. The oncogenic roles of NTRK fusions and methods of molecular diagnosis. Aref-Eshghi E; Lin F; Li MM; Zhong Y Cancer Genet; 2021 Nov; 258-259():110-119. PubMed ID: 34710798 [TBL] [Abstract][Full Text] [Related]
4. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing. Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853 [TBL] [Abstract][Full Text] [Related]
5. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Marchiò C; Scaltriti M; Ladanyi M; Iafrate AJ; Bibeau F; Dietel M; Hechtman JF; Troiani T; López-Rios F; Douillard JY; Andrè F; Reis-Filho JS Ann Oncol; 2019 Sep; 30(9):1417-1427. PubMed ID: 31268127 [TBL] [Abstract][Full Text] [Related]
6. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing. Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039 [TBL] [Abstract][Full Text] [Related]
7. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. Hsiao SJ; Zehir A; Sireci AN; Aisner DL J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511 [TBL] [Abstract][Full Text] [Related]
8. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population. Zhao R; Yao F; Xiang C; Zhao J; Shang Z; Guo L; Ding W; Ma S; Yu A; Shao J; Zhu L; Han Y J Pathol Clin Res; 2021 Jul; 7(4):375-384. PubMed ID: 33768710 [TBL] [Abstract][Full Text] [Related]
17. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes. Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998 [TBL] [Abstract][Full Text] [Related]
18. NTRK fusions and Trk proteins: what are they and how to test for them. Weiss LM; Funari VA Hum Pathol; 2021 Jun; 112():59-69. PubMed ID: 33794242 [TBL] [Abstract][Full Text] [Related]
19. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform. Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612 [No Abstract] [Full Text] [Related]
20. Feasibility of two-step approach for screening NTRK fusion in two major subtypes of non-small cell lung cancer within a large cohort. Dong K; Zhu Y; Liu X; Sun W; Yang X; Chi K; Jia L; Diao X; Huang X; Zhou L; Lin D Hum Pathol; 2024 Jul; 149():39-47. PubMed ID: 38866255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]